ABSTRACT
Introduction Inter-individual response to dietary interventions remains a major challenge to successful weight loss among older adults. This study applied metabolomics technology to identify small molecule signatures associated with loss of fat mass and overall weight in a cohort of older adults on a nutritionally complete, high protein diet.
Methods 102 unique metabolites were measured using LC-MS for 38 adults aged 65-80 years randomized to dietary intervention and 36 controls. Metabolite values were analyzed in both baseline plasma samples and samples collected following the six-month dietary intervention to consider both metabolites that could predict response to diet and those that changed in response to diet or weight loss.
Results Eight metabolites changed over intervention at a nominally-significant level: D-pantothenic acid, L-methionine, nicotinate, aniline, melatonin, deoxycarnitine, 6-deoxy-L-galactose, and 10-hydroxydecanoate. Within the intervention group, there was broad variation in achieved weight-loss and DXA-defined changes in total fat and visceral adipose tissue (VAT) mass. Change in VAT mass was significantly associated with baseline abundance of α-aminoadipate (p = 0.0007) and an additional mass spectrometry peak that may represent D-fructose, myo-inositol, mannose, α-D-glucose, allose, D-galactose, D-tagatose, or L-sorbose (p = 0.0001).
Discussion This hypothesis-generating study reflects the potential of metabolomic biomarkers for the development of personalized dietary interventions.
Competing Interest Statement
Medifast, Inc. provided partial funding for the study and made an in-kind product donation for the meal replacements used in the study. The terms of this arrangement were reviewed and approved by Wake Forest University Health Sciences in accordance with its conflict of interest policies.
Funding Statement
This work was supported by a grant from Jason Pharmaceuticals, Inc., a wholly owned subsidiary of Medifast, Inc., as well as the Wake Forest Claude D. Pepper Older Americans Independence Center (P30 AG21332) and Proteomics and Metabolomics Shared Resource Core (P30CA012197). Support was also provided by the National Institute on Aging through an exploratory and developmental grant (R21 AG061344) to KMB, DPB, and CF, career development award (K01 AG056663) to EQ and postdoctoral fellowship (T32 AG033534) to RM.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Wake Forest School of Medicine IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Submission of metabolomic data to the NIH metabolomics workbench is pending.